(Q60699516)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

European consensus proposal for immunoglobulin therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

0 references

Jacqueline Kerr

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Marie-Emmanuelle Behr-Gross

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hans-Hartmut Peter

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

W A Carrock Sewell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Kreuth Ig Working Group

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

1 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

2207-2214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

Haemophilia care in Europe - a survey of 35 countries

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Advances in the treatment of primary and secondary immune deficiences

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

The European internet-based patient and research database for primary immunodeficiencies: update 2011.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Genomic responses in mouse models poorly mimic human inflammatory diseases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulin products.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Management of Kawasaki disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Prioritization of evidence-based indications for intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous immunoglobulin: striving for appropriate use.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Natural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Tregitope peptides: the active pharmaceutical ingredient of IVIG?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous immunoglobulins--understanding properties and mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Cell death modulation by intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

What is IgG4? A review of the biology of a unique immunoglobulin subtype

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201444700

7 January 2021

Identifiers

DOI

10.1002/EJI.201444700

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975475%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference